{
    "clinical_study": {
        "@rank": "48615", 
        "arm_group": {
            "arm_group_label": "Diagnostic (SLN mapping, biopsy, surgery)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy."
        }, 
        "brief_summary": {
            "textblock": "This clinical trial studies lymph node mapping in patients with newly diagnosed endometrial\n      cancer undergoing surgery. Lymph node mapping may help in planning surgery to remove\n      endometrial cancer and affected lymph nodes."
        }, 
        "brief_title": "Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery", 
        "condition": [
            "Stage IA Endometrial Carcinoma", 
            "Stage IB Endometrial Carcinoma", 
            "Stage II Endometrial Carcinoma", 
            "Stage IIIA Endometrial Carcinoma", 
            "Stage IIIB Endometrial Carcinoma", 
            "Stage IIIC Endometrial Carcinoma", 
            "Stage IVA Endometrial Carcinoma", 
            "Stage IVB Endometrial Carcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Endometrial Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the detection rate, sensitivity, and negative predictive value of sentinel\n      lymph node (SLN) biopsy in endometrial cancer patients.\n\n      SECONDARY OBJECTIVES:\n\n      I. To compare different surgical modalities (open procedures, minimally invasive procedures,\n      and single-site technology) and different injectants (isosulfan blue and indocyanine green)\n      for SLN biopsy.\n\n      II. To determine total operating room time (from the time the patient enters the room to the\n      time the patient leaves the room) as well as console time (robotic)/operating time for\n      minimally invasive procedures.\n\n      OUTLINE:\n\n      Patients undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected\n      directly into the cervix. Following SLN identification and biopsy, patients undergo\n      hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy.\n      Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.\n\n      After completion of study treatment, patients are followed up at 2-4 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women must have newly diagnosed histologically or cytologically confirmed endometrial\n             cancer\n\n          -  Women should have received no prior therapy for their disease\n\n          -  Women who are planning to undergo hysterectomy, bilateral salpingo-oophorectomy, and\n             pelvic lymphadenectomy for the management of their endometrial cancer\n\n          -  Women must have the ability to understand and the willingness to sign a written\n             informed consent document\n\n        Exclusion Criteria:\n\n          -  Women who are receiving any other investigational agents\n\n          -  Women with a history of allergic reactions attributed to compounds of similar\n             chemical or biologic composition to isosulfan blue or indocyanine green or other\n             agents used in this study\n\n          -  Women with hypersensitivity to phenylmethane compounds, or a history of allergic\n             reaction to iodides\n\n          -  Patients with uncontrolled intercurrent illness including, but not limited to ongoing\n             or active infection, symptomatic congestive heart failure, unstable angina pectoris,\n             cardiac arrhythmia, or psychiatric illness/social situations that would limit\n             compliance with study requirements\n\n          -  Women with a history of prior loop electrosurgical excision procedure (LEEP) or cone\n             procedures performed on their cervix\n\n          -  Women with a history of lymphedema, lymphoma, or lymphatic hyperplasia (Castleman\n             disease)\n\n          -  Women with a history of a prior malignancy\n\n          -  Women may also be excluded at the discretion of their surgeon if he or she feels that\n             the patient is not an appropriate candidate"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01939028", 
            "org_study_id": "CASE9813", 
            "secondary_id": [
                "NCI-2013-01309", 
                "P30CA043703"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Diagnostic (SLN mapping, biopsy, surgery)", 
                "description": "Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution", 
                "intervention_name": "lymph node mapping", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Diagnostic (SLN mapping, biopsy, surgery)", 
                "description": "Undergo SLN biopsy", 
                "intervention_name": "sentinel lymph node biopsy", 
                "intervention_type": "Procedure", 
                "other_name": "sentinel node biopsy"
            }, 
            {
                "arm_group_label": "Diagnostic (SLN mapping, biopsy, surgery)", 
                "description": "Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution", 
                "intervention_name": "isosulfan blue", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Lymphazurin", 
                    "N-[4-[4-(diethylamino)phenyl] (2,5-disulfophenyl) Methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium hydroxide"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (SLN mapping, biopsy, surgery)", 
                "description": "Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution", 
                "intervention_name": "indocyanine green solution", 
                "intervention_type": "Drug", 
                "other_name": [
                    "IC-GREEN", 
                    "ICG solution"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (SLN mapping, biopsy, surgery)", 
                "description": "Undergo hysterectomy, bilateral salpingo-oophorectomy and/or complete pelvic lymphadenectomy", 
                "intervention_name": "therapeutic conventional surgery", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Diagnostic (SLN mapping, biopsy, surgery)", 
                "description": "Undergo para-aortic lymphadenectomy", 
                "intervention_name": "lymphadenectomy", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 6, 2014", 
        "location": {
            "contact": {
                "email": "michenc@ccf.org", 
                "last_name": "Chad Michener, MD", 
                "phone": "216-444-6601"
            }, 
            "facility": {
                "address": {
                    "city": "Cleveland", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "44195"
                }, 
                "name": "Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center"
            }, 
            "investigator": {
                "last_name": "Chad Michener, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Sentinel Lymph Node Mapping for Endometrial Cancer", 
        "overall_official": {
            "affiliation": "Case Comprehensive Cancer Center", 
            "last_name": "Chad Michener, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Sensitivity estimated as the proportion of true positives among patients with lymph node metastases. Sensitivity Calculation= the number of patients with a positive SLN over those patients with a positive SLN plus those patients with a false negative lymph node.\nSensitivity, specificity, and negative predictive value of SLN biopsy for detecting metastasis will be estimated and appropriate 95% confidence intervals for each value will be provided.", 
                "measure": "Sensitivity of Sentential Lymph Node (SLN) biopsy", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 weeks"
            }, 
            {
                "description": "Number of patients in whom a sentinel node is detected.", 
                "measure": "Detection Rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 weeks"
            }, 
            {
                "description": "False negative rate = 1-sensitivity or the number of patients with a false negative SLN over the number of patients with a positive SLN plus those with a false negative lymph node", 
                "measure": "False Negative Rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01939028"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The number of true positive sentinel lymph nodes identified will be compared between the surgical modalities using pairwise comparisons for each surgical modality. Comparisons will be performed using two sample tests of proportions based on a normal approximation.", 
                "measure": "Comparison of surgical modalities (open procedures, minimally invasive procedures, and single-site technology)", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 weeks"
            }, 
            {
                "description": "The number of true positive sentinel lymph nodes identified will be compared between injectants utilized using a two sample test of proportions based on a normal approximation. Comparisons will be performed using two sample tests of proportions based on a normal approximation.", 
                "measure": "Comparison between isosulfan blue and indocyanine green solution", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 weeks"
            }, 
            {
                "description": "Total operating room time will be estimated as a mean with 95% confidence interval if the data have an approximately normal distribution. Otherwise, the median and a bootstrapped 95% confidence interval for the median will be reported. Similar summaries will be provided for the console time (robotic)/ operating time.", 
                "measure": "Total operating room time", 
                "safety_issue": "No", 
                "time_frame": "From the time the patient enters the room to the time the patient leaves the room, assessed up to 4 weeks"
            }
        ], 
        "source": "Case Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Case Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}